Several studies have identified the PTPN22 allelic variant 1858 C/T that encodes the R620W amino-acid change as a putative susceptibility factor in autoimmune diseases. The current study was undertaken to examine a large cohort of Finnish rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) subjects using both population control and, importantly, familybased association methods. The latter is particularly important when, as is the case for the 1858 C/T polymorphism, the frequency of the variant allele (T) differs in both major ancestral populations and in subpopulations. The analysis of rheumatoid factor-positive 1030 RA probands from Finland provides strong support for association of this variant in both population studies (allele specific odds ratio (OR) ¼ 1.47, 95% confidence interval (CI) ¼ 1.27-1.70, P ¼ 3 Â 10
The identification of PTPN22 1858 C/T as a putative disease risk allele in type 1 diabetes (T1D) [1] [2] [3] [4] [5] [6] and subsequently RA [7] [8] [9] and other autoimmune diseases including SLE, 10, 11 Graves disease 12 and JIA 9 has engendered considerable excitement. 13 PTPN22 also known as LYP (lymphocyte phosphatase) encodes a hematopoietic tissue-specific protein tyrosine phosphatase that is thought to inhibit T-cell activation through its association with the Csk tyrosine kinase. 14, 15 The W620 variant is a nonconservative amino-acid substitution in the proximal proline-rich SH3-binding domain that disrupts the interaction with Csk. 1, 7 Thus, this variant could lead to hyperactivity of T cells, a characteristic of many autoimmune diseases. Alternatively, decreased PTPN22 function is also potentially linked to B-cell autoreactivity (reviewed in Siminovitch 13 ) and the effects of the W620 variant in other hematopoietic cells have not been adequately investigated.
Recent association studies of T1D, RA and SLE in diverse European populations have shown (1) association of the variant allele and specific autoimmune diseases in Northern, Eastern, Southern European and mixed European derived populations; (2) disparate 1858T allele frequencies in control subjects in different regions in Europe (eg Sardinia allele frequency ¼ 0.023; Norway ¼ 0.116); 1, 6 and (3) absence of the allele in Han Chinese subjects. 7 Importantly, for T1D, the casecontrol findings have been strongly supported by family-based studies in which the results cannot be explained by hidden population stratification. 2, 3 In the current study, a transmission disequilibrium test was utilized to address this concern with regard to association of the W620 allele with RA. This test or other methods that control for population substructure are essential when allele frequencies appear to diverge among populations. As shown in Table 1 , the Finnish control population has the highest reported allele frequency in any population studied to date (0.155), further emphasizing the potential for false-positive results in case-control studies.
The analysis of the PTPN22 1858 C/T genotypes in 1030 Finnish RF-positive RA patients and 1400 controls showed strong evidence of both allelic and genotypic association by contingency table analysis (Table 1) and logistic regression (data not shown). The OR for RA susceptibility was 1.47 for individuals carrying the T allele, similar to that observed in other European populations. Also similar to other studies, there was no difference when gender or age of onset was considered in the logistic regression analyses (data not shown). The data also clearly indicated a gene dosage effect of the T allele with TT homozygotes showing nearly a three-fold greater risk (3.58 vs 1.23) than heterozygotes (Table 1) . This increased risk for TT homozygotes is consistent with that observed in other RA case-control studies 7, 8, 21 and similar to findings in both T1D and SLE. 7 Analysis of 429 RA simplex families using a transmission disequilibrium test also showed strong evidence for association (Table 2) consistent with the population association tests. The examination of a confirmed erosive subset of patients, and those patients with early-onset disease showed effects similar to the overall subject group in both the population control study (data not shown, results of the population age of onset analysis already mentioned above) and in the family-based analysis (Table 2) . Although the HLA-shared epitope was not examined in the current study, these results are consistent with previous studies that did not show any evidence of genetic association of the PTPN22 and HLA susceptibility alleles. 8 In contrast to the results found for RA, the analyses of 230 JIA probands showed minimal evidence for association both in the population-based study and in the transmission disequilibrium testing (Tables 1  and 2 ). Only marginally significant association was found for the carriage of the homozygous variant (P ¼ 0.023). When JIA subsets were examined, only the polyarticular subset showed marginal significance and only in the TDT analysis (P ¼ 0.03). No association was observed when either those subjects with early-onset disease (prior to age 6) or when subsets containing or not containing the JIA HLA 'shared epitope' 17 were considered (Table 2 and data not shown). These JIA results do not support the findings of a previous study, which suggested that the PTPN22 1858T allele variant is associated with this disease. 9 However, the relatively small sample size (230 probands in the current study) does not preclude a modest effect from this gene in Finnish JIA. Differences in results between the current study and the previous study performed in Norwegian subjects may also be explained by differences between populations or the possibility of hidden population structure that was not controlled for in the previous study.
Overall, the current study provides further support for the contribution of the PTPN22 W620 variant as a susceptibility allele for RA. Critically, the family-based analyses were consistent with the population association test. Thus, taken together with previous studies, the PTPN22 W620 risk allele appears to contribute a modest (OR range ¼ 1.45-1.97 for all studies to date) but real risk to RA susceptibility in many European or Europeanderived or -related populations. The large variance in the allele frequency of this polymorphism between various European populations, particularly those with known founder effects, suggests that careful control for population stratification is critical in examination of the association of this allele in RA and other autoimmune diseases. All subjects were Finnish speaking and recruited in Finland under institutionally approved informed consent. For RA, all subjects met ACR criteria and were RF positive. For JIA, all subjects met the definition for the new classification of JIA. 16 The JIA patients consisted of 82 probands with persistant oligoarthritis and 152 probands with polyarticular RF-negative subset classification. All B27-positve patients were excluded. A more complete description of these subjects is provided in Rundstadler et al. 17-19 b Genotyping of the PTPN22 (1858 C/T) SNP was performed using a TaqMan Assay-By-Design (Applied Biosystems) on the ABI 7900 Analyzer. The PCR primers were: forward, TDT analysis performed using FBAT program 22 in which a testing statistic of transmission (S) is compared with the expected value (E(S)) and its variance (Var(S)). Combined set included both persistant oligoarthritis (PO) and polyarticular RF subsets (PA). Early onset (EO) included both PO and PA with the onset prior to age 6. All B27-positive subjects were excluded from these data sets.
